Wolfe Research Upgrades Warner Bros. Discovery as Max Sees Improvement
Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...
Fintel on MSN6h
Wolfe Research Initiates Coverage of Pfizer (PFE) with Underperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Pfizer (NYSE:PFE) with a Underperform ...
Fintel on MSN8h
Wolfe Research Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Wolfe Research starts BioMarin at Outperform given its blockbuster with Voxzogo
Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...
bovnews1h
Why Is Hess Corp (HES) Stock Surpassing 6.46% from Its 50-Day SMA?
On Friday, Hess Corp (HES) stock saw a modest uptick, ending the day at $145.64 which represents a slight increase of $0.58 or 0.40% from the prior close of $145.06. The stock opened at $144.67 and ...
bovnews1d
Wolfe Research Just Resumed ConocoPhillips (COP) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...
Wolfe upgrades Warner Bros. Discovery as trends at Max improve
Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...
Warner Bros. Discovery stock upgraded at Wolfe on re-bundling trends
Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ: NASDAQ: WBD) to Peer Perform from ...
Nasdaq4d
Wolfe Research Downgrades Alnylam Pharmaceuticals (LSE:0HD2)
Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...